Document is current
Any future updates will be listed below
-
Authors
Ikegami, Tetsuro https://orcid.org/0000-0001-8318-2783
Jurado-Cobena, Eduardo https://orcid.org/0000-0002-8832-4645
Alkan, Cigdem https://orcid.org/0000-0002-1302-9270
Smith, Jennifer K.
Zhang, Lihong
Kalveram, Birte
Juelich, Terry L.
Esterly, Allen T. https://orcid.org/0000-0003-1132-6797
Bhaskar, Jahnavi R.
Thangamani, Saravanan
Freiberg, Alexander N. https://orcid.org/0000-0001-8413-8960
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01 AI150917-01)
- License Information
-
More Information
Article History
Received: 18 April 2022
Accepted: 1 September 2022
First Online: 21 September 2022
Competing interests
: T.I. has a pending patent for RVax-1 vaccine submitted through UTMB (US17/067,144). Authors E.J-C., C.A., J.K.S., L.Z., B.K., T.L.J., A.T.E., J.R.B., S.T., and A.N.F. declare no competing interests.
